Search research articles
Contact Us
Filters
Showing results (1-10 of 115) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 23, 2021
Is Osimertinib-Induced Cardiotoxicity Really Harmless?
Kei Kunimasa
Thoracic Cancer
|
October 19, 2020
Is the case really a SMARCA4-deficient thoracic sarcoma?
Kei Kunimasa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 22, 2023
Notch Mutations as a Novel Biomarker for Immunotherapy
Kei Kunimasa
Lung Cancer (Amsterdam, Netherlands)
|
January 20, 2021
A reply to "Cardiac dysfunction due to Osimertinib"
Kei Kunimasa
The New England Journal of Medicine
|
March 26, 2026
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3
Kei Kunimasa
International Journal of Molecular Sciences
|
January 23, 2020
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kei Kunimasa, Taichiro Goto
Annals of Translational Medicine
|
April 30, 2019
Is an immune checkpoint inhibitor really a hopeless therapeutic choice for <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC) patients?
Kei Kunimasa, Kazumi Nishino, Toru Kumagai
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 21, 2017
Erlotinib Is Effective for Leptomeningeal Carcinomatosis due to Disease Flare after Osimertinib Treatment Failure
Kei Kunimasa, Chihiro Mimura, Yoshikazu Kotani
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 22, 2023
Severe Psychosis Associated With Lorlatinib
Kei Kunimasa, Makoto Wada, Kazumi Nishino
Discover Oncology
|
February 10, 2025
Driver mutation detected in cerebrospinal fluid despite negative liquid biopsy results
Kei Kunimasa, Daisuke Aohara, Kazumi Nishino
Page
of 12
Search research articles
Search
Showing results (1-10 of 115) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 23, 2021
Is Osimertinib-Induced Cardiotoxicity Really Harmless?
Kei Kunimasa
Thoracic Cancer
|
October 19, 2020
Is the case really a SMARCA4-deficient thoracic sarcoma?
Kei Kunimasa
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 22, 2023
Notch Mutations as a Novel Biomarker for Immunotherapy
Kei Kunimasa
Lung Cancer (Amsterdam, Netherlands)
|
January 20, 2021
A reply to "Cardiac dysfunction due to Osimertinib"
Kei Kunimasa
The New England Journal of Medicine
|
March 26, 2026
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3
Kei Kunimasa
International Journal of Molecular Sciences
|
January 23, 2020
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kei Kunimasa, Taichiro Goto
Annals of Translational Medicine
|
April 30, 2019
Is an immune checkpoint inhibitor really a hopeless therapeutic choice for <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC) patients?
Kei Kunimasa, Kazumi Nishino, Toru Kumagai
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 21, 2017
Erlotinib Is Effective for Leptomeningeal Carcinomatosis due to Disease Flare after Osimertinib Treatment Failure
Kei Kunimasa, Chihiro Mimura, Yoshikazu Kotani
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 22, 2023
Severe Psychosis Associated With Lorlatinib
Kei Kunimasa, Makoto Wada, Kazumi Nishino
Discover Oncology
|
February 10, 2025
Driver mutation detected in cerebrospinal fluid despite negative liquid biopsy results
Kei Kunimasa, Daisuke Aohara, Kazumi Nishino
Page
of 12